Tarcocimab’s ocular half-life in humans was calculated by measuring aqueous humor concentrations over time from patients in the Phase 1b Study 1 10 100 1000 10000 100000 0 4 8 12 16 20 24 28 • Aqueous humor samples were collected from 47 subjects in the tarcocimab Phase 1b study in patients with wet AMD, DME and RVO and were used to evaluate tarcocimab ocular half life in patients • Aqueous humor samples were collected at baseline and at Week 4, 12, 14, 16, 18, 20 and 24 and measured for tarcocimab concentrations • Samples collected between the last loading dose and the next re-dose were used to determine ocular half-life of tarcocimab Using Aqueous Humor Concentration of Tarcocimab to Determine Ocular t1/2 in human Weeks Tarcocimab aqueous humor concentration (ng/ml) AH samples from Week 12 – 24 were used to determine tarcocimab t1/2 3 loading doses of intravitreal injections of 5mg tarcocimab Data from one individual patient from the Phase 1b study of tarcocimab is used to illustrate the methodology here. Patients received as-needed redosing after week 8 and aqueous humor samples collected after a redose were excluded from the analysis 20